Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Immunosuppressants Market: By Drug Class, Calcineurin Inhibitors, mTOR Inhibitors, Anti-Proliferative Agents, Others), By Indication, By Route of Administration, By Distribution Channel and Geography
Immunosuppressants Market size was valued at US$ 62.46 billion in 2023 and is poised to grow at a CAGR of 14.2% from 2024-2030. Immunosuppressants or anti-rejections are the medicinal substances, which prevent or inhibit the immune system activity. Immunosuppressants are most commonly used in organ transplantation, and autoimmune disorders such as Crohn’s disease, multiple sclerosis, rheumatoid arthritis, and among others. Moreover, immunosuppressants are also used in some non-autoimmune inflammatory diseases such as ankylosing spondylitis.
Immunodeficiency is the major adverse effect associated with immunosuppressants as these drugs act non-selectively and increase the susceptibility to infections. In addition, dyslipidemia, peptic ulcers, hypertension, kidney injury, hyperglycemia, and hepatic injuries are other adverse effects of immunosuppressants. The immunosuppressants market is growing at a significant CAGR owing to an increase in the prevalence of autoimmune disorders and the incidence of organ transplantation. For instance, According to the World Health Organization, in 2014, approximately 119,873 organ transplantation cases were observed, which was an increase of about 1.8% from 2013. Furthermore, various pipeline products in the market are also expected to bolster the market over the forecast period. Acquisitions & mergers, collaborations, and product launches are the strategies followed by the companies to increase their revenue in the immunosuppressants market.
Study Period
2024-2030Base Year
2023CAGR
14.2%Largest Market
North AmericaFastest Growing Market
Asia Pacific
Increase in the incidence of organ failure and there by rising demand for organ transplantation, technological advancements in organ transplantation procedures, and increase in the prevalence of autoimmune diseases are the factors anticipated to fuel the immunosuppressants market over the forecast period. Moreover, favourable reimbursement policies for immunosuppressants, development of newer therapeutic drugs, and various pipeline products might fuel the immunosuppressants market over the forecast period. However, stringent regulatory policies for drug approval, alternative therapies such as stem cell therapy for immunosuppression, and lack of awareness about immunosuppressants are the factors expected to hamper the growth of immunosuppressants market over the forecast period.
Report Benchmarks |
Details |
Report Study Period |
2024-2030 |
Market Size in 2023 |
US$ 62.46 billion |
Market CAGR |
14.2% |
By Drug Class |
|
By Indication |
|
By Route Administration |
|
By Distribution Channel |
|
Download Free Sample Report
The immunosuppressants market size was valued at US$ 61.54 billion in 2023
Technological Advancements in Tissue Engineering and Organ Transplantations
Asia Pacific is the fastest-growing for immunosuppressants market
1.Executive Summary |
2.Global Immunosuppressants Market Introduction |
2.1.Global Immunosuppressants Market - Taxonomy |
2.2.Global Immunosuppressants Market - Definitions |
2.2.1.By Drug Class |
2.2.2.By Indication |
2.2.3.By Route Administration |
2.2.4.By Distribution Channel |
2.2.5.Region |
3.Global Immunosuppressants Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Product Landscape |
3.6. New Product Launches |
3.7. Impact of COVID 19 on Market |
4.Global Immunosuppressants Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5.Global Immunosuppressants Market By By Drug Class, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
5.1. Corticosteroids |
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Monoclonal Antibodies (mAbs) |
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. Calcineurin Inhibitors |
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
5.4. mTOR Inhibitors |
5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.4.3. Market Opportunity Analysis |
5.5. Anti-Proliferative Agents |
5.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.5.3. Market Opportunity Analysis |
5.6. Others |
5.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.6.3. Market Opportunity Analysis |
6.Global Immunosuppressants Market By By Indication, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
6.1. Organ Transplantation |
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Autoimmune Disorders |
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Non-Autoimmune Inflammatory Diseases |
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
7.Global Immunosuppressants Market By By Route Administration, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
7.1. Oral |
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Parenteral |
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
8.Global Immunosuppressants Market By By Distribution Channel, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
8.1. Hospital pharmacies |
8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Retail pharmacies |
8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
8.3. Online pharmacies |
8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.3.3. Market Opportunity Analysis |
9.Global Immunosuppressants Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
9.1. North America |
9.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
9.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.1.3. Market Opportunity Analysis |
9.2. Europe |
9.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
9.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.2.3. Market Opportunity Analysis |
9.3. Asia Pacific (APAC) |
9.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
9.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.3.3. Market Opportunity Analysis |
9.4. Middle East and Africa (MEA) |
9.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
9.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.4.3. Market Opportunity Analysis |
9.5. Latin America |
9.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
9.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.5.3. Market Opportunity Analysis |
10.North America Immunosuppressants Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
10.1. By Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.1.1.Corticosteroids |
10.1.2.Monoclonal Antibodies (mAbs) |
10.1.3.Calcineurin Inhibitors |
10.1.4.mTOR Inhibitors |
10.1.5.Anti-Proliferative Agents |
10.1.6.Others |
10.2. By Indication Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.2.1.Organ Transplantation |
10.2.2.Autoimmune Disorders |
10.2.3.Non-Autoimmune Inflammatory Diseases |
10.3. By Route Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.3.1.Oral |
10.3.2.Parenteral |
10.4. By Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.4.1.Hospital pharmacies |
10.4.2.Retail pharmacies |
10.4.3.Online pharmacies |
10.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.5.1.United States of America (USA) |
10.5.2.Canada |
11.Europe Immunosuppressants Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
11.1. By Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.1.1.Corticosteroids |
11.1.2.Monoclonal Antibodies (mAbs) |
11.1.3.Calcineurin Inhibitors |
11.1.4.mTOR Inhibitors |
11.1.5.Anti-Proliferative Agents |
11.1.6.Others |
11.2. By Indication Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.2.1.Organ Transplantation |
11.2.2.Autoimmune Disorders |
11.2.3.Non-Autoimmune Inflammatory Diseases |
11.3. By Route Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.3.1.Oral |
11.3.2.Parenteral |
11.4. By Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.4.1.Hospital pharmacies |
11.4.2.Retail pharmacies |
11.4.3.Online pharmacies |
11.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.5.1.Germany |
11.5.2.France |
11.5.3.Italy |
11.5.4.United Kingdom (UK) |
11.5.5.Spain |
12.Asia Pacific (APAC) Immunosuppressants Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
12.1. By Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.1.1.Corticosteroids |
12.1.2.Monoclonal Antibodies (mAbs) |
12.1.3.Calcineurin Inhibitors |
12.1.4.mTOR Inhibitors |
12.1.5.Anti-Proliferative Agents |
12.1.6.Others |
12.2. By Indication Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.2.1.Organ Transplantation |
12.2.2.Autoimmune Disorders |
12.2.3.Non-Autoimmune Inflammatory Diseases |
12.3. By Route Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.3.1.Oral |
12.3.2.Parenteral |
12.4. By Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.4.1.Hospital pharmacies |
12.4.2.Retail pharmacies |
12.4.3.Online pharmacies |
12.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.5.1.China |
12.5.2.India |
12.5.3.Australia and New Zealand (ANZ) |
12.5.4.Japan |
12.5.5.Rest of APAC |
13.Middle East and Africa (MEA) Immunosuppressants Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
13.1. By Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.1.1.Corticosteroids |
13.1.2.Monoclonal Antibodies (mAbs) |
13.1.3.Calcineurin Inhibitors |
13.1.4.mTOR Inhibitors |
13.1.5.Anti-Proliferative Agents |
13.1.6.Others |
13.2. By Indication Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.2.1.Organ Transplantation |
13.2.2.Autoimmune Disorders |
13.2.3.Non-Autoimmune Inflammatory Diseases |
13.3. By Route Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.3.1.Oral |
13.3.2.Parenteral |
13.4. By Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.4.1.Hospital pharmacies |
13.4.2.Retail pharmacies |
13.4.3.Online pharmacies |
13.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.5.1.GCC Countries |
13.5.2.South Africa |
13.5.3.Rest of MEA |
14.Latin America Immunosuppressants Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
14.1. By Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.1.1.Corticosteroids |
14.1.2.Monoclonal Antibodies (mAbs) |
14.1.3.Calcineurin Inhibitors |
14.1.4.mTOR Inhibitors |
14.1.5.Anti-Proliferative Agents |
14.1.6.Others |
14.2. By Indication Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.2.1.Organ Transplantation |
14.2.2.Autoimmune Disorders |
14.2.3.Non-Autoimmune Inflammatory Diseases |
14.3. By Route Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.3.1.Oral |
14.3.2.Parenteral |
14.4. By Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.4.1.Hospital pharmacies |
14.4.2.Retail pharmacies |
14.4.3.Online pharmacies |
14.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.5.1.Brazil |
14.5.2.Mexico |
14.5.3.Rest of LA |
15. Competition Landscape |
15.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
15.2.1.GlaxoSmithKline Plc. (U.K.) |
15.2.2.Novartis AG (Switzerland) |
15.2.3.Sanofi S.A. (France) |
15.2.4.Pfizer, Inc. (U.S.) |
15.2.5.Bristol Myers Squibb (U.S.) |
15.2.6.F. Hoffmann La Roche Ltd. (Switzerland) |
15.2.7.Astellas Pharma, Inc. (Japan) |
15.2.8.Zydus Cadila (India) |
15.2.9.Genzyme Corporation (U.S.) |
16. Research Methodology |
17. Appendix and Abbreviations |
Key Market Players